The most recent trading session ended with McKesson (MCK) standing at $518.81, reflecting a +1.49% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily gain of 0.54%. Meanwhile, the Dow experienced a rise of 0.72%, and the technology-dominated Nasdaq saw an increase of 0.65%.Heading into today, shares of the prescription drug distributor had lost 6.28% over the past month, lagging the Medical sector's gain of 4.37% and the S&P 500's gain of 4.86% in that time.Investors will ...

The most recent trading session ended with McKesson (MCK) standing at $511.17, reflecting a +0.14% shift from the previouse trading day's closing. This change lagged the S&P 500's 0.75% gain on the day. Elsewhere, the Dow saw an upswing of 0.58%, while the tech-heavy Nasdaq appreciated by 1%.The prescription drug distributor's shares have seen a decrease of 7.67% over the last month, not keeping up with the Medical sector's gain of 3.55% and the S&P 500's gain of 4.03%.The investment community will be payin ...

McKesson Corporation (MCK) has agreed to sell its Rexall and Well.ca businesses, both based in Canada, to Birch Hill Equity Partners, a Canadian private equity firm. The deal supports McKesson's strategic decision to concentrate on expanding its oncology and biopharma services while maintaining its focus on the Canadian healthcare market through distribution and biopharma. Through this transaction, Rexall and Well.ca will benefit from Birch Hill's commitment to investing in growth and expanding services acr ...

Key TakeawaysThe S&P 500 slid 0.3% on Thursday, Sept. 5, with soft private payroll data adding to concerns about the labor market ahead of Friday's jobs report.McKesson shares plunged after the medical products distributor announced plans to sell its Canada-based Rexall and Well.ca businesses.Dollar Tree shares moved higher, clawing back some of the steep losses in the previous session. Major U.S. equities indexes were mixed as the latest ADP jobs data showed a smaller-than-expected jump in private payrolls ...

McKesson Corporation (NYSE:MCK) Wells Fargo 2024 Healthcare Conference September 5, 2024 8:45 AM ET Company Participants Britt Vitalone - Executive Vice President and Chief Financial Officer Conference Call Participants Stephen Baxter - Wells Fargo Stephen Baxter Good morning. I'm Steve Baxter, the Healthcare Services Analyst at Wells Fargo. We're really pleased to have McKesson with us today. As I'm sure you know, McKesson is the largest drug distributor in the United States, also operates Pharma Services ...

McKesson (MCK) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Individual in ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Let's take a look at what these Wall Street heavyweights have to say about McKesson (MCK) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.McKesson currently has an average brokerage recommendation (ABR) ...

McKesson Corporation (MCK) , on Monday, inked a definitive agreement to acquire a controlling interest (representing approximately 70% ownership) in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures), subject to customary closing conditions. Florida Cancer Specialists & Research Institute, LLC (“FCS”) physicians will retain a minority interest in Core Ventures.Core Ventures, a business and administrative services organization, was established by FCS.Following the completion of the tr ...

McKesson (MCK) is witnessing strong momentum, with its shares having rallied 18.3% year to date compared with 0.6% growth of the industry. The S&P 500 Composite has risen 16.5% during the same time frame.With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment.Headquartered in San Francisco, CA, McKesson is a healthcare services and information technology company with two operating segments — Distributio ...

McKesson (MCK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Over the past month, shares of this prescription drug distributor have returned -5%, compared to the Zacks S&P 500 composite's -2.9% change. During this period, the Zacks Medical - Dental Supplies industry, which McKesson falls in, has gained 0.1%. The key question now is: What could be the stock's future direction?A ...